The aim of this investigation was to spotlight the utility of nuclear magnetic resonance (NMR) as a multi-attribute methodology for the characterization of therapeutic antibodies. On this case examine, we in contrast outcomes from isothermal chemical denaturation (ICD) and NMR with commonplace strategies to narrate conformational states of a mannequin monoclonal antibody (mAb1) with protein-protein interactions (PPI) that result in self – affiliation in concentrated options.
The rise in aggregation fee and relative viscosity for mAb1 was discovered to be each focus and pH dependent. The free vitality of unfolding (∆G⁰) from ICD and thermal evaluation in dilute options indicated that though the native state predominated between pH 4 – pH 7, it was disrupted on the CH2 and unfolded noncooperatively underneath acidic situations.
One-dimensional (1D) 1H NMR and two-dimensional (2D) 13C-1H NMR carried out, in concentrated options, confirmed that PPI between pH 4 – 7 occurred whereas mAb1 was within the native state. NMR corroborated that mAb1 maintained a dominant native state at formulation-relevant situations on the examined pH vary, had elevated world molecular tumbling dynamics at decrease pH and confirmed elevated PPI at larger pH situations.
This report aligns and compares typical characterization of an IgG1 with evaluation of construction by NMR and supplied a extra exact evaluation and deeper perception into the conformation of an IgG1 in concentrated options.
Elevated mycobacterium avium subsp. paratuberculosis (MAP) antibody titer in Japanese a number of sclerosis
To research whether or not antibody manufacturing in opposition to mycobacterium avium subsp. paratuberculosis (MAP) is said to scientific traits of a number of sclerosis (MS) and human leukocyte antigen (HLA) alleles, IgG antibody in opposition to three MAP peptides and two human peptides homologous to MAP had been measured in sera from 103 MS sufferers and 50 wholesome controls (HCs).
MS sufferers had larger IgG ranges in opposition to MAP2694295-303 (MAP2694-IgG) than HCs, whereas the opposite antibodies had been comparable. Multivariate evaluation demonstrated that larger MAP2694-IgG titers had been related to larger EDSS scores, however not with HLA alleles or dairy product consumption. Immune response in opposition to MAP could worsen MS incapacity.
Predominant mesangial IgM, C3, and λ gentle chain depositions and interstitial nephritis in a affected person with overlap syndrome and positivity for anti-mitochondrial M2 antibody: a case report
Overlap syndrome refers to a gaggle of situations which have scientific options of a couple of well-characterised rheumatic illness and meet the respective classification standards. There aren’t any typical renal histological findings in overlap syndrome. When sufferers with overlap syndrome develop renal dysfunction, varied potential causes, together with lupus nephritis (LN), renal disaster by systemic sclerosis, interstitial nephritis, and so forth, should be distinguished.
Right here, we report a 44-year-old lady with overlap syndrome involving systemic lupus erythematosus (SLE), diffuse cutaneous systemic scleroderma, and Sjogren’s syndrome, who was additionally optimistic for anti-mitochondrial M2 antibody. She developed glomerular haematuria, proteinuria, and enhance in creatinine appeared regularly.
Suspecting LN, renal biopsy was carried out. Nonetheless, within the interstitium, gentle infiltration of lymphocytes and plasma cells and really partial fibrosis had been noticed. Immunofluorescence microscopy revealed predominant mesangial immunoglobulin M, C3, and λ gentle chain staining. General, LN was not recognized primarily based on these findings.
Renal dysfunction was normalised by glucocorticoid remedy for three months. This case suggests the significance of a renal analysis primarily based on renal pathological findings, particularly in a case of overlap syndrome together with SLE.
A Japanese Affected person with Anti-PM/Scl and Centromere Antibody-Constructive Scleroderma-Amyopathic Dermatomyositis Overlap Syndrome Who Developed Renal Disaster
Anti-PM/Scl antibodies are related to the overlap syndrome of systemic sclerosis and dermatomyositis/polymyositis (SSc-DM/PM), and are present in 50% of SSc-DM/PM instances in Europe and the USA, whereas they’re uncommon in Japan. We report a case of an 80-year-old Japanese feminine with SSc-amyopathic dermatomyositis (ADM) overlap syndrome, who developed scleroderma renal disaster (SRC), a complication of SSc.
She had optimistic antinuclear antibodies in a discrete-speckled and nucleolar sample and anticentromere antibodies and anti-PM/Scl antibodies had been confirmed by ELISA and immunoprecipitation, respectively. The incidence fee of SRC in SSc sufferers varies considerably relying on the specificity of autoantibodies, with the very best incidence of ~50% in anti-RNA polymerase III antibody optimistic sufferers, adopted by ~10% in anti-PM/Scl and decrease incidence of 0.45% in anticentromere antibody-positive instances.
Anti-PM/Scl antibodies are unusual in Japanese sufferers presumably because of its robust affiliation with sure HLA haplotype that’s uncommon in Japanese. Scientific significance of anti-PM/Scl antibodies in Japanese sufferers will should be clarified with accumulation of instances in future research.
Intrinsic physicochemical profile of marketed antibody-based biotherapeutics
Feeding biopharma pipelines with biotherapeutic candidates that possess fascinating developability profiles will help enhance the productiveness of biologic drug discovery and improvement. Right here, we’ve got derived an in silico profile by analyzing computed physicochemical descriptors for the variable areas (Fv) present in 77 marketed antibody-based biotherapeutics. Fv areas of those biotherapeutics show vital diversities of their germlines, complementarity figuring out area loop lengths, hydrophobicity, and cost distributions.
Moreover, an evaluation of 24 physicochemical descriptors, calculated utilizing homology-based molecular fashions, has yielded 5 nonredundant descriptors whose distributions symbolize stability, isoelectric level, and molecular floor traits of their Fv areas. Fv areas of candidates from our inner discovery campaigns, human next-generation sequencing repertoires, and people in clinical-stages (CST) had been assessed for similarity with the physicochemical profile derived right here.
The Fv areas in 33% of CST antibodies present physicochemical properties which are dissimilar to presently marketed biotherapeutics. As compared, physicochemical traits of ∼29% of the Fv areas in human antibodies and ∼27% of our inner hits deviated considerably from these of marketed biotherapeutics.
 CD146 Antibody |
|
49868-100ul |
SAB |
100ul |
EUR 399.6 |
CD146 Antibody |
|
49868-50ul |
SAB |
50ul |
EUR 286.8 |
 CD146 antibody |
|
10R-6489 |
Fitzgerald |
100 ug |
EUR 249.6 |
|
Description: Mouse monoclonal CD146 antibody |
CD146 Antibody |
|
20-abx242914 |
Abbexa |
|
|
|
|
 anti-CD146 |
|
YF-PA13077 |
Abfrontier |
50 ug |
EUR 435.6 |
|
Description: Mouse polyclonal to CD146 |
) CD146 antibody (biotin) |
|
61R-CD146aHUBT |
Fitzgerald |
100 tests |
EUR 625.2 |
|
Description: Mouse monoclonal CD146 antibody (biotin) |
 Antibody) MCAM(CD146) Antibody |
|
48005-100ul |
SAB |
100ul |
EUR 399.6 |
MCAM(CD146) Antibody |
|
48005-50ul |
SAB |
50ul |
EUR 286.8 |
) CD146 Antibody (FITC) |
|
abx200496-100tests |
Abbexa |
100 tests |
EUR 477.6 |
|
|
) CD146 Antibody (Biotin) |
|
abx200500-100ug |
Abbexa |
100 ug |
EUR 460.8 |
|
|
 CD146 Conjugated Antibody |
|
C49868 |
SAB |
100ul |
EUR 476.4 |
 Anti-CD146 antibody |
|
STJ190008 |
St John's Laboratory |
200 µl |
EUR 236.4 |
|
Description: Unconjugated Mouse monoclonal to CD146 (AS1A31) |
 Anti-Hu CD146 Purified |
|
11-783-C025 |
ExBio |
0.025 mg |
EUR 118.8 |
Anti-Hu CD146 Purified |
|
11-783-C100 |
ExBio |
0.1 mg |
EUR 189.6 |
 Anti-Hu CD146 PE |
|
1P-783-T025 |
ExBio |
25 tests |
EUR 168 |
Anti-Hu CD146 PE |
|
1P-783-T100 |
ExBio |
100 tests |
EUR 288 |
 CD146 recombinant monoclonal antibody |
|
A5098 |
Bimake |
100ul X 3 |
EUR 714 |
|
|
|
Description: A recombinant monoclonal antibody from rabbit against human CD146 for WB, IF,ELISA |
 Conjugated Antibody) MCAM(CD146) Conjugated Antibody |
|
C48005 |
SAB |
100ul |
EUR 476.4 |
 anti- CD146/MCAM antibody |
|
FNab01428 |
FN Test |
100µg |
EUR 606.3 |
|
|
|
Description: Antibody raised against CD146/MCAM |
anti- CD146/MCAM antibody |
|
FNab01429 |
FN Test |
100µg |
EUR 702 |
|
|
|
Description: Antibody raised against CD146/MCAM |
 Anti-CD146/MCAM Antibody |
|
PA1736 |
BosterBio |
100ug/vial |
EUR 400.8 |
Anti-CD146/MCAM Antibody |
|
RP1050 |
BosterBio |
100ug/vial |
EUR 400.8 |
 CD146 Monoclonal Antibody [RMC563A] |
|
A68401-050 |
EpiGentek |
50 ul |
EUR 350.9 |
CD146 Monoclonal Antibody [RMC563A] |
|
A68401-100 |
EpiGentek |
100 ul |
EUR 470.8 |
CD146 Monoclonal Antibody [RMC563A] |
|
A68401 |
EpiGentek |
-
EUR 754.26
-
EUR 350.90
-
EUR 470.80
|
|
) CD146/MCAM Antibody (CT) |
|
6801-100 |
Biovision |
each |
EUR 379.2 |
 CD146 Antibody / MCAM / MUC18 |
|
V8923-100UG |
NSJ Bioreagents |
100ug |
EUR 499 |
|
Description: The human MCAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated Mel-CAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. MCAM expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. MCAM is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V8923-20UG |
NSJ Bioreagents |
20ug |
EUR 219 |
|
Description: The human MCAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated Mel-CAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. MCAM expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. MCAM is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V8923SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 499 |
|
Description: The human MCAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated Mel-CAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. MCAM expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. MCAM is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V2696-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. MCAM expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V2696-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. MCAM expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V2696IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. MCAM expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V2696SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. MCAM expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V2697-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. CD146 expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V2697-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. CD146 expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V2697IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. CD146 expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V2697SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. CD146 expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V2698-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
|
Description: The human CD146 gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. CD146 expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V2698-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
|
Description: The human CD146 gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. CD146 expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V2698IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
|
Description: The human CD146 gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. CD146 expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V2698SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
|
Description: The human CD146 gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. CD146 expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V2699-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. CD146 expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V2699-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. CD146 expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V2699IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. CD146 expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V2699SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. CD146 expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V3638-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
|
Description: CD146 expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V3638-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
|
Description: CD146 expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V3638IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
|
Description: CD146 expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V3638SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
|
Description: CD146 expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. It is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V7138-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
|
Description: CD146/MUC18/MCAM plays a role in cell adhesion, and in cohesion of the endothelial monolayer at intercellular junctions in vascular tissue. Its expression may allow melanoma cells to interact with cellular elements of the vascular system, thereby enhancing hematogeneous tumor spread. Could be an adhesion molecule active in neural crest cells during embryonic development. Acts as surface receptor that triggers tyrosine phosphorylation of FYN and PTK2/FAK1, and a transient increase in the intracellular calcium concentration. [UniProt] |
CD146 Antibody / MCAM / MUC18 |
|
V7138-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
|
Description: CD146/MUC18/MCAM plays a role in cell adhesion, and in cohesion of the endothelial monolayer at intercellular junctions in vascular tissue. Its expression may allow melanoma cells to interact with cellular elements of the vascular system, thereby enhancing hematogeneous tumor spread. Could be an adhesion molecule active in neural crest cells during embryonic development. Acts as surface receptor that triggers tyrosine phosphorylation of FYN and PTK2/FAK1, and a transient increase in the intracellular calcium concentration. [UniProt] |
CD146 Antibody / MCAM / MUC18 |
|
V7138IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
|
Description: CD146/MUC18/MCAM plays a role in cell adhesion, and in cohesion of the endothelial monolayer at intercellular junctions in vascular tissue. Its expression may allow melanoma cells to interact with cellular elements of the vascular system, thereby enhancing hematogeneous tumor spread. Could be an adhesion molecule active in neural crest cells during embryonic development. Acts as surface receptor that triggers tyrosine phosphorylation of FYN and PTK2/FAK1, and a transient increase in the intracellular calcium concentration. [UniProt] |
CD146 Antibody / MCAM / MUC18 |
|
V7138SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
|
Description: CD146/MUC18/MCAM plays a role in cell adhesion, and in cohesion of the endothelial monolayer at intercellular junctions in vascular tissue. Its expression may allow melanoma cells to interact with cellular elements of the vascular system, thereby enhancing hematogeneous tumor spread. Could be an adhesion molecule active in neural crest cells during embryonic development. Acts as surface receptor that triggers tyrosine phosphorylation of FYN and PTK2/FAK1, and a transient increase in the intracellular calcium concentration. [UniProt] |
 Cd146 Antibody / MCAM / MUC18 |
|
RQ5987 |
NSJ Bioreagents |
100 ug |
EUR 419 |
|
Description: In humans, the CD146 protein is encoded by the MCAM gene. It is mapped to 9; 9 A5.1. CD146 (cluster of differentiation 146) also known as the melanoma cell adhesion molecule (MCAM) or cell surface glycoprotein MUC18, is a 113kDa cell adhesion molecule currently used as a marker for endothelial cell lineage. MCAM functions as a receptor for laminin alpha 4, a matrix molecule that is broadly expressed within the vascular wall. Accordingly, MCAM is highly expressed by cells that are components of the blood vessel wall, including vascular endothelial cells, smooth muscle cells and pericytes. Its function is still poorly understood, but evidence points to it being part of the endothelial junction associated with the actin cytoskeleton. A member of the Immunoglobulin superfamily, it consists of five Ig domains, a transmembrane domain, and a cytoplasmic region. It is expressed on chicken embryonic spleen and thymus, activated human T cells, endothelial progenitors such as angioblasts and mesenchymal stem cells, and strongly expressed on blood vessel endothelium and smooth muscle. |
CD146 Antibody / MCAM / MUC18 |
|
V2189-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. MUC18 expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. MUC18 / CD146 is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V2189-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. MUC18 expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. MUC18 / CD146 is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V2189SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. MUC18 expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. MUC18 / CD146 is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V7942-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. Mel-CAM expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. Mel-CAM is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V7942-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. Mel-CAM expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. Mel-CAM is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V7942SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. Mel-CAM expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. Mel-CAM is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V7943-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. Mel-CAM expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. Mel-CAM is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V7943-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. Mel-CAM expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. Mel-CAM is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
CD146 Antibody / MCAM / MUC18 |
|
V7943SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
|
Description: The human Mel-CAM gene maps to chromosome 11q23 and encodes a trans-membrane glycoprotein, also designated MCAM, MUC 18 or CD146, that belongs to the immunoglobulin superfamily and functions as a Ca2+-independent cell adhesion molecule. Mel-CAM expression is restricted to advanced primary and metastatic melanomas and to cell lines of the neuroectodermal lineage, but not normal melanocytes. Mel-CAM is found on 80% of advanced primary human melanomas and correlates well with development of metastatic disease. |
) Polyclonal CD146/MCAM Antibody (CT) |
|
APR00368G |
Leading Biology |
0.1ml |
EUR 580.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human CD146/MCAM (CT). This antibody is tested and proven to work in the following applications: |
 Anti-CD146 Rabbit Monoclonal Antibody |
|
M01683-1 |
BosterBio |
100ug/vial |
EUR 476.4 |
|
Description: Rabbit Monoclonal CD146 Antibody. Validated in IP, IF, IHC, WB and tested in Human, Mouse, Rat. |
 Recombinant Human CD146/MCAM Protein |
|
RP00101 |
Abclonal |
20 μg |
EUR 448.8 |
Anti-CD146 Rabbit Monoclonal Antibody |
|
A1122-50 |
Biovision |
each |
EUR 430.8 |
 Antibody) Cell Surface Glycoprotein MUC18 (CD146) Antibody |
|
abx139732-01mg |
Abbexa |
0.1 mg |
EUR 427.2 |
|
|
Cell Surface Glycoprotein MUC18 (CD146) Antibody |
|
abx019043-100ug |
Abbexa |
100 ug |
EUR 410.4 |
|
|
Cell Surface Glycoprotein MUC18 (CD146) Antibody |
|
abx200495-100ug |
Abbexa |
100 ug |
EUR 393.6 |
|
|
Cell Surface Glycoprotein MUC18 (CD146) Antibody |
|
20-abx225287 |
Abbexa |
-
EUR 444.00
-
EUR 727.20
-
EUR 376.80
|
|
|
|
Cell Surface Glycoprotein MUC18 (CD146) Antibody |
|
abx413746-02mg |
Abbexa |
0.2 mg |
EUR 678 |
|
|
Cell Surface Glycoprotein MUC18 (CD146) Antibody |
|
abx413749-25ug |
Abbexa |
25 ug |
EUR 326.4 |
|
|
Cell Surface Glycoprotein MUC18 (CD146) Antibody |
|
abx413750-1mg |
Abbexa |
1 mg |
EUR 994.8 |
|
|
Cell Surface Glycoprotein MUC18 (CD146) Antibody |
|
abx231428-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
|
Cell Surface Glycoprotein MUC18 (CD146) Antibody |
|
abx231429-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
|
 Antibody) MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC040676-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF405S conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC040676-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF405S conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC050676-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF405M conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC050676-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF405M conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNCAP0676-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNCAP0676-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNCB0676-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), Biotin conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNCB0676-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), Biotin conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNCP0676-250 |
Biotium |
250uL |
EUR 459.6 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), PerCP conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNCR0676-250 |
Biotium |
250uL |
EUR 459.6 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), RPE conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC940676-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF594 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC940676-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF594 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNCA0676-250 |
Biotium |
250uL |
EUR 459.6 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), APC conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC810676-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF680R conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC810676-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF680R conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNUB0676-100 |
Biotium |
100uL |
EUR 250.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), Concentration: 0.2mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNUB0676-500 |
Biotium |
500uL |
EUR 549.6 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), Concentration: 0.2mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNCH0676-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNCH0676-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC880676-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF488A conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC880676-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF488A conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC680676-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF568 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC680676-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF568 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC470676-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF647 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC470676-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF647 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC400676-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF640R conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC400676-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF640R conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC430676-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF543 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC430676-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF543 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC550676-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF555 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC550676-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF555 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC610676-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF660R conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC610676-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF660R conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC800676-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF680 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC800676-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF680 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC700676-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF770 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNC700676-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), CF770 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(OJ79c) Antibody |
|
BNUM0676-50 |
Biotium |
50uL |
EUR 474 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(OJ79c), 1mg/mL |
 Human MCAM/CD146 PicoKine ELISA Kit |
|
EK1675 |
BosterBio |
96 wells |
EUR 510 |
|
Description: For Quantitative Detection of human MCAM in cell culture supernates and serum. |
 Antibody (PE)) Cell Surface Glycoprotein MUC18 (CD146) Antibody (PE) |
|
abx139733-100tests |
Abbexa |
100 tests |
EUR 577.2 |
|
|
Cell Surface Glycoprotein MUC18 (CD146) Antibody (PE) |
|
abx200497-100tests |
Abbexa |
100 tests |
EUR 543.6 |
|
|
 Antibody (APC)) Cell Surface Glycoprotein MUC18 (CD146) Antibody (APC) |
|
abx200498-100tests |
Abbexa |
100 tests |
EUR 543.6 |
|
|
 Antibody (PerCP)) Cell Surface Glycoprotein MUC18 (CD146) Antibody (PerCP) |
|
abx200499-100tests |
Abbexa |
100 tests |
EUR 543.6 |
|
|
 Antibody (FITC)) Cell Surface Glycoprotein MUC18 (CD146) Antibody (FITC) |
|
abx413747-01mg |
Abbexa |
0.1 mg |
EUR 693.6 |
|
|
Cell Surface Glycoprotein MUC18 (CD146) Antibody (FITC) |
|
abx413748-25ug |
Abbexa |
25 ug |
EUR 360 |
|
|
 Antibody) MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNC041130-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF405S conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNC041130-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF405S conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNCAP1130-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNCAP1130-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNCB1130-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), Biotin conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNCB1130-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), Biotin conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNCP1130-250 |
Biotium |
250uL |
EUR 459.6 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), PerCP conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNCR1130-250 |
Biotium |
250uL |
EUR 459.6 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), RPE conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNC941130-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF594 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNC941130-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF594 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNCA1130-250 |
Biotium |
250uL |
EUR 459.6 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), APC conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNC811130-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF680R conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNC811130-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF680R conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNUB1130-100 |
Biotium |
100uL |
EUR 250.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), Concentration: 0.2mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNUB1130-500 |
Biotium |
500uL |
EUR 549.6 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), Concentration: 0.2mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNCH1130-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNCH1130-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNC881130-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF488A conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNC881130-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF488A conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNC611130-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF660R conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNC611130-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF660R conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNC681130-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF568 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNC681130-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF568 conjugate, Concentration: 0.1mg/mL |
MUC18 / Mucin 18 / CD146(MUC18/1130) Antibody |
|
BNC431130-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against MUC18 / Mucin 18 / CD146(MUC18/1130), CF543 conjugate, Concentration: 0.1mg/mL |
The early availability of this data will help information hit choice, lead identification, and optimization of biotherapeutic candidates. Insights from this work can even assist help portfolio threat evaluation, in-licensing, and biopharma collaborations.
